This trial is active, not recruiting.

Conditions abdominal aortic aneurysm, coronary heart disease nos, unheralded coronary death, intracerebral haemorrhage, heart failure, ischemic stroke, myocardial infarction, stroke, peripheral arterial disease, stable angina pectoris, subarachnoid haemorrhage, transient ischemic attack, unstable angina, cardiac arrest, sudden cardiac death
Sponsor University College, London
Collaborator Wellcome Trust
Start date January 2012
End date December 2013
Trial size 1961286 participants
Trial identifier NCT01947361, 12_153R_IP10, RP-PG-0407-10314


Study of heterogeneity in associations between heart rate and the initial presentation of 12 cardiovascular diseases.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

Risk of atherosclerotic disease in patients with high or low heart rate
time frame: Participants were followed until the first Coronary disease event (an expected average of 5 years)

Secondary Outcomes

Incidence proportions and life time risk for Cardiovascular diseases
time frame: Participants were followed until the first Coronary disease event (an expected average of 5 years)

Eligibility Criteria

Male or female participants at least 30 years old.

Inclusion Criteria: - One year prior to study entry (up-to-standard follow-up, CPRD quality research standard). - > 30 years old - have at least a recorded heart rate measurement during the study period Exclusion Criteria: - Evidence of prior atherosclerotic or cardiac disease

Additional Information

Official title Heterogeneity in Association of Heart Rate and Initial Presentation of Cardiovascular Diseases Using Linked Electronic Health Records
Description This study is part of the CALIBER (Cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the NIHR and Wellcome Trust. The central theme of the CALIBER research is linkage of the Myocardial Ischaemia National Audit Project (MINAP) with primary care (GPRD) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).
Trial information was received from ClinicalTrials.gov and was last updated in September 2013.
Information provided to ClinicalTrials.gov by University College, London.